BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sickle Cell Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Sickle Cell Disease\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04819841-10290@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nula-cel: Phase 1/2 readout est. (NCT04819841)
DESCRIPTION:Nula-cel\, phase 1/2\, Sickle Cell Disease.\nStudy: Gene Correc
 tion in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Se
 vere Sickle Cell Disease\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nula-cel#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04819841
URL:https://assetmemo.bio/drug/nula-cel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293185-10297@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lovotibeglogene autotemcel (Lyfgenia): Phase 3 readout est. (NCT042
 93185)
DESCRIPTION:Lovotibeglogene autotemcel (Lyfgenia)\, phase 3\, Sickle Cell D
 isease.\nStudy: A Study Evaluating Gene Therapy With BB305 Lentiviral Vect
 or in Sickle Cell Disease\nEstimated primary completion: May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lovotibeglogene-autotemcel-l
 yfgenia#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04293185
URL:https://assetmemo.bio/drug/lovotibeglogene-autotemcel-lyfgenia#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05329649-10277@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT053296
 49)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Safety and Efficacy of CTX001 in Pediatric Part
 icipants With Severe Sickle Cell Disease (SCD)\nEstimated primary completi
 on: 6 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/exag
 amglogene-autotemcel-casgevy#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05329649
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05477563-10277@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT054775
 63)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: Evaluation of Efficacy and Safety of a Single Dose of CTX001 
 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickl
 e Cell Disease\nEstimated primary completion: 9 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0547756
 3
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05953584-10273@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Etavopivat: Phase 2 readout est. (NCT05953584)
DESCRIPTION:Etavopivat\, phase 2\, Sickle Cell Disease.\nStudy: A Phase 2 O
 pen-label Study to Evaluate the Activity of Etavopivat on Transcranial Dop
 pler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at 
 Increased Risk for Primary Stroke\nEstimated primary completion: 20 August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595358
 4
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612268-10273@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:Etavopivat: Phase 3 readout est. (NCT06612268)
DESCRIPTION:Etavopivat\, phase 3\, Sickle Cell Disease.\nStudy: A Study to 
 Evaluate How Well Etavopivat Works in People With Sickle Cell Disease\nEst
 imated primary completion: 27 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/etavopivat#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06612268
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05456880-10266@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ristoglogene autogetemcel: Phase 1/2 readout est. (NCT05456880)
DESCRIPTION:Ristoglogene autogetemcel\, phase 1/2\, Sickle Cell Disease.\nS
 tudy: BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Pa
 tients With Severe Sickle Cell Disease\nEstimated primary completion: Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ristogloge
 ne-autogetemcel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05456880
URL:https://assetmemo.bio/drug/ristoglogene-autogetemcel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578507-10310@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Hydroxyurea (Siklos): Phase 2 readout est. (NCT06578507)
DESCRIPTION:Hydroxyurea (Siklos)\, phase 2\, Sickle Cell Disease.\nStudy: P
 harmacokinetics\, Efficacy and Safety of Twice Daily Dosing Regimen of Hyd
 roxycarbamide Dispersible Tablets in Children With Sickle Cell Disease\nEs
 timated primary completion: February 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/hydroxyurea-siklos#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06578507
URL:https://assetmemo.bio/drug/hydroxyurea-siklos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06198712-10273@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:Etavopivat: Phase 2 readout est. (NCT06198712)
DESCRIPTION:Etavopivat\, phase 2\, Sickle Cell Disease.\nStudy: A Study to 
 Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patien
 ts With Sickle Cell Disease\nEstimated primary completion: 23 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06198712
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04610866-10280@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pyrukynd (Mitapivat): Phase 1/2 readout est. (NCT04610866)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 1/2\, Sickle Cell Disease.\nStudy:
  Safety\, Tolerability\, Pharmacokinetics\, and Pharmacodynamics of Long-t
 erm Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Exten
 sion of a Phase I Pilot Study of Mitapivat\nEstimated primary completion: 
 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mit
 apivat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04610866
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06546670-10298@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:ITU512: Phase 1/2 readout est. (NCT06546670)
DESCRIPTION:ITU512\, phase 1/2\, Sickle Cell Disease.\nStudy: A Phase I/II 
 Study of ITU512 in Healthy Participants and Patients With Sickle Cell Dise
 ase\nEstimated primary completion: 1 May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/itu512#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06546670
URL:https://assetmemo.bio/drug/itu512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05469828-10308@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:crizanlizumab-tmca (Adakveo): Phase 1/2 readout est. (NCT05469828)
DESCRIPTION:crizanlizumab-tmca (Adakveo)\, phase 1/2\, Sickle Cell Disease.
 \nStudy: Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Pa
 tients With Sickle Cell Anemia\nEstimated primary completion: 1 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/crizanlizumab-tmca-a
 dakveo#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05469828
URL:https://assetmemo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439082-10308@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:crizanlizumab-tmca (Adakveo): Phase 3 readout est. (NCT06439082)
DESCRIPTION:crizanlizumab-tmca (Adakveo)\, phase 3\, Sickle Cell Disease.\n
 Study: A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 
 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease P
 atients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)\nEstimated
  primary completion: 2 July 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06439082
URL:https://assetmemo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07656415-10280@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pyrukynd (Mitapivat): Phase 3 readout est. (NCT07656415)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 3\, Sickle Cell Disease.\nStudy: A
  Study to Investigate the Effect of Mitapivat on Transfusion Burden in Sub
 jects With Sickle Cell Disease (SCD)\nEstimated primary completion: August
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitapivat#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07656415
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708714-10310@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Hydroxyurea (Siklos): Phase 1/2 readout est. (NCT07708714)
DESCRIPTION:Hydroxyurea (Siklos)\, phase 1/2\, Sickle Cell Disease.\nStudy:
  Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Mal
 aria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study\nEstimat
 ed primary completion: 30 November 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/hydroxyurea-siklos#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07708714
URL:https://assetmemo.bio/drug/hydroxyurea-siklos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06609226-10273@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Etavopivat: Phase 3 readout est. (NCT06609226)
DESCRIPTION:Etavopivat\, phase 3\, Sickle Cell Disease.\nStudy: A Research 
 Study Looking at Long-term Treatment With Etavopivat in People With Sickle
  Cell Disease or Thalassaemia\nEstimated primary completion: 30 December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/etavopivat#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06609226
URL:https://assetmemo.bio/drug/etavopivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208529-10277@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20390930
DTEND;VALUE=DATE:20391001
SUMMARY:Exagamglogene autotemcel (Casgevy): Phase 3 readout est. (NCT042085
 29)
DESCRIPTION:Exagamglogene autotemcel (Casgevy)\, phase 3\, Sickle Cell Dise
 ase.\nStudy: A Long-term Follow-up Study in Participants Who Received CTX0
 01\nEstimated primary completion: 30 September 2039. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04208529
URL:https://assetmemo.bio/drug/exagamglogene-autotemcel-casgevy#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
